Ocugen Inc (OCGN) has dosed its first patient in a phase 3 trial of its OCU410 modifier gene therapy as a potential treatment for geographic atrophy secondary to dry age-related macular degeneration, the company said Tuesday.
The drug is designed as a one-time subretinal gene therapy, the company said.
The placebo-controlled study has enrolled 237 patients, the company said.
The company plans to file a biologics license application for the therapy in 2028, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.